drug
Ketorolac Tromethamine Apotex
Marketedupdated 3mo agoby Apotex Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugtromethamine11 co-mentions · 11 sources
- drugKETOROLAC TROMETHAMINE11 co-mentions · 11 sources
- drugketorolac11 co-mentions · 11 sources
- tagApproval10 co-mentions · 5 sources
- tagRecall4 co-mentions · 4 sources
- companyApotex Corp4 co-mentions · 2 sources
- companyAspiro Pharma Ltd2 co-mentions · 1 sources
- tagDrug Shortage2 co-mentions · 2 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 9 investigational indications.
all catalysts(5)
approval · 5
Nov 5, 2009
approval
KETOROLAC TROMETHAMINE — FDA approval
Ketorolac Tromethamine Apotex
→
Mar 28, 2013
approval
KETOROLAC TROMETHAMINE — FDA approval
Ketorolac Tromethamine Apotex
→
Dec 11, 2015
approval
KETOROLAC TROMETHAMINE — FDA approval
Ketorolac Tromethamine Apotex
→
Sep 5, 2018
approval
KETOROLAC TROMETHAMINE — FDA approval
Ketorolac Tromethamine Apotex
→
Jan 22, 2026
approval
KETOROLAC TROMETHAMINE — FDA approval
Ketorolac Tromethamine Apotex
→
Trials studying Ketorolac Tromethamine Apotex
- —Anesthetics and Analgesics in Children
- phase3Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy
- phase4Ketorolac Effects on Post-operative Pain and Lumbar Fusion
- phase1Treatment of Topical Ketorolac Gel in Acute Gouty Flare
- phase2Efficacy and Safety of Escócia Association in the Treatment of Acute Pain
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 24, 2027
282 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Apr 23, 2034patentUS 9066856*PED
- Apr 23, 2034patentUS 9486406*PED
- Oct 23, 2033formulationUS 9066856
- Oct 23, 2033formulationUS 9486406
- Oct 23, 2033formulationUS 9855246
- Aug 15, 2029compositionUS 78427143.0y
- Mar 7, 2028formulationUS 85127171.6y
- Mar 7, 2028formulationUS 91925711.6y
- Nov 24, 2027patentUS 8008338*PED1.3y
- May 24, 2027compositionUS 8008338282d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that